NovoCure Limited (NVCR) Stock

Healthcare · Medical Devices · Member of Other US Stocks

NovoCure Limited (NVCR) closed at USD 13.84 on 2026-10-14, a change of +3.5 % over the past year, with a market capitalization of USD 1.68B.

NovoCure Limited recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

NovoCure Limited key figures

Previous close

USD 13.84 (2026-10-14)

1-year change

+3.5 %

Market cap

USD 1.68B

Enterprise value

USD 1.47B

P/E ratio (trailing)

-11.00

P/E ratio (forward)

-17.87

EPS (trailing)

-1.31

EPS (forward)

-0.81

PEG ratio

n/a

Price to book

4.96

Revenue growth

15.6 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

10.35

Employees

1,605

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About NovoCure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for NovoCure Limited and compare it with other stocks.